Contineum Therapeutics, Inc. (NASDAQ:CTNM) Shares Acquired by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC grew its holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 817.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 82,234 shares of the company's stock after buying an additional 73,267 shares during the period. ADAR1 Capital Management LLC owned approximately 0.32% of Contineum Therapeutics worth $1,205,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Corebridge Financial Inc. increased its position in shares of Contineum Therapeutics by 73.1% during the 4th quarter. Corebridge Financial Inc. now owns 5,215 shares of the company's stock valued at $76,000 after purchasing an additional 2,202 shares during the last quarter. Rhumbline Advisers increased its position in Contineum Therapeutics by 36.3% during the fourth quarter. Rhumbline Advisers now owns 8,233 shares of the company's stock valued at $121,000 after acquiring an additional 2,191 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Contineum Therapeutics by 1,248.6% in the third quarter. BNP Paribas Financial Markets now owns 6,743 shares of the company's stock valued at $129,000 after acquiring an additional 6,243 shares during the period. Barclays PLC raised its stake in shares of Contineum Therapeutics by 248.6% in the third quarter. Barclays PLC now owns 8,308 shares of the company's stock valued at $158,000 after acquiring an additional 5,925 shares during the period. Finally, Wells Fargo & Company MN raised its position in Contineum Therapeutics by 419.3% in the 4th quarter. Wells Fargo & Company MN now owns 10,755 shares of the company's stock worth $158,000 after purchasing an additional 8,684 shares during the period.

Contineum Therapeutics Price Performance

NASDAQ:CTNM traded down $0.12 during trading hours on Friday, reaching $4.01. The company had a trading volume of 66,573 shares, compared to its average volume of 77,178. The business's 50 day moving average price is $6.97 and its 200-day moving average price is $12.16. Contineum Therapeutics, Inc. has a 1-year low of $3.91 and a 1-year high of $22.00. The firm has a market cap of $103.75 million and a PE ratio of -0.82.

Analysts Set New Price Targets

CTNM has been the subject of several research analyst reports. Jones Trading began coverage on Contineum Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $23.00 target price for the company. Robert W. Baird decreased their price objective on shares of Contineum Therapeutics from $32.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, March 7th. Morgan Stanley restated an "overweight" rating and issued a $25.00 target price on shares of Contineum Therapeutics in a research note on Friday, March 7th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $31.00 price target on shares of Contineum Therapeutics in a research note on Thursday, January 9th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $24.80.

Contineum Therapeutics Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).